April 24, 2018 / 10:11 AM / a month ago

BRIEF-Lilly Says Galcanezumab Reduced Monthly Migraine Headache Days In Patients With Migraine

April 24 (Reuters) - Eli Lilly and Co:

* AAN 2018: LILLY’S GALCANEZUMAB SIGNIFICANTLY REDUCED MONTHLY MIGRAINE HEADACHE DAYS IN PATIENTS WITH MIGRAINE WHO PREVIOUSLY FAILED TO RESPOND TO MULTIPLE PREVENTIVE THERAPIES

* ELI LILLY AND CO - U.S. FOOD AND DRUG ADMINISTRATION (FDA) IS REVIEWING GALCANEZUMAB FOR PREVENTION OF MIGRAINE IN ADULTS

* ELI LILLY AND CO - DECISION FOR GALCANEZUMAB IS EXPECTED IN Q3 OF 2018

* ELI LILLY AND CO - ALSO IS EVALUATING GALCANEZUMAB FOR TREATMENT OF CLUSTER HEADACHE WITH PHASE 3 TRIAL RESULTS EXPECTED IN Q2 OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below